Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6 ... a novel IL-6R inhibitor, may be beneficial for the treatment of RA in ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

Corvidia’s lead drug candidate – interleukin-6 inhibitor ziltivekimab (formerly COR-001) – is being developed as a therapy for reducing the risk of cardiovascular problems in CKD who have ...

Creative Biolabs recently updated its antibody chip platform, expanding product arrays for phosphorylation signaling and ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

The cDNAs encoding RAF1 mutants were generated by PCR and inserted into pCDNA3.1(+) vector with N-terminal FLAG tag. Plasmids were transfected into 293T cells by using lipofectamine 2000 (Invitrogen), ...

May 15, 2025 — A new study suggests that gabapentin, a relatively common anti-seizure/pain medication, is linked to improved survival in patients with glioblastoma (GBM) -- the most common and ...